Hackensack, NJ - March 15, 2023 – Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its third quarter of fiscal 2023, ended January 31, 2023.
Champions Oncology
Recent Posts
Champions Oncology Reports Quarterly Revenue of $12.8 Million
Mar 16, 2023 5:10:07 PM / by Champions Oncology
Champions Oncology Reports Record Quarterly Revenue of $14.3 Million
Dec 14, 2022 12:38:59 PM / by Champions Oncology
Hackensack, NJ - December 13, 2022 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its second quarter of fiscal 2023, ended October 31, 2022.
Champions Oncology Reports Record Quarterly Revenue of $13.7 Million
Sep 9, 2022 11:38:02 AM / by Champions Oncology
Hackensack, NJ - September 8, 2022 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its first quarter of fiscal 2023, ended July 31, 2022.
Champions Oncology Reports Quarterly Revenue of $12.9 Million
Jul 23, 2022 6:58:54 PM / by Champions Oncology
Hackensack, NJ - July 21, 2022 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for the year and fourth fiscal quarter ended April 30, 2022.
Champions Oncology Announces a Partnership with Cyclica to Develop Small Molecule Therapeutics
May 31, 2022 8:33:17 AM / by Champions Oncology
Hackensack, NJ and Toronto, ON – May 31, 2022 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, and Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, announced today a therapeutic development partnership.
